A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol

David Pryor, Mathias Bressel, Nathan Lawrentschuk, Ben Tran, Jennifer Mooi, Jeremy Lewin, Arun Azad, Duncan Colyer, Nitika Neha, Mark Shaw, Sarat Chander, Paul Neeson, Daniel Moon, Katharine Cuff, Simon Wood, Declan G Murphy, Shahneen Sandhu, Sherene Loi, Shankar Siva, David Pryor, Mathias Bressel, Nathan Lawrentschuk, Ben Tran, Jennifer Mooi, Jeremy Lewin, Arun Azad, Duncan Colyer, Nitika Neha, Mark Shaw, Sarat Chander, Paul Neeson, Daniel Moon, Katharine Cuff, Simon Wood, Declan G Murphy, Shahneen Sandhu, Sherene Loi, Shankar Siva

Abstract

Background: The management of oligometastatic clear cell renal cell carcinoma (ccRCC) varies widely, ranging from observation to resection or systemic therapies. Prolonged survival has been observed following resection or stereotactic ablative body radiotherapy (SABR). Immunotherapy combinations have shown survival benefits, however, toxicity is higher than that for monotherapy and complete response rates remain less than 10%. The combination of effective local therapies in conjunction with immunotherapy may provide more durable control and pre-clinical models have suggested a synergistic immune-priming effect of SABR.

Objectives: and Methods: RAPPORT is a prospective, single arm, phase I/II study assessing the safety, efficacy and biological effects of single fraction SABR followed by pembrolizumab for oligometastatic ccRCC. The study will include 30 patients with histological confirmed ccRCC and 1-5 oligometastases, one or more of which must be suitable for SABR. Patients can have received prior systemic therapy but not prior immunotherapy. A single 20Gy of SABR is followed 5 days later by 8 cycles of 200 mg pembrolizumab, every 3 weeks. Adverse events are recorded using CTCAE V4.03 and tumour response evaluated by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1). Tumour tissue and peripheral blood samples will be collected pre-, during and post-treatment to assess longitudinal changes in immune subsets.

Outcomes and significance: The RAPPORT study will provide important safety and early efficacy data on the combination of SABR and pembrolizumab in oligometastatic ccRCC and will provide an insight into the underlying biological effects of combination therapy.

Trial registration: clinicaltrials.gov ID NCT02855203.

Keywords: Immunotherapy; Oligometastases; RCC; Renal cell carcinoma; SABR; SBRT.

© 2021 Published by Elsevier Inc.

References

    1. Australian Institute of Health and Welfare . AIHW; Canberra: 2019. Cancer in Australia 2019. Cancer Series no.119. Cat. No. CAN 123.
    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca - Cancer J. Clin. 2018 Nov;68(6):394–424.
    1. Chow W.H., Devesa S.S., Warren J.L., Fraumeni J.F., Jr. Rising incidence of renal cell cancer in the United States. J. Am. Med. Assoc.: J. Am. Med. Assoc. 1999;281(17):1628–1631.
    1. Kane C.J., Mallin K., Ritchey J., Cooperberg M.R., Carroll P.R. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008;113(1):78.
    1. Maldazys J.D., deKernion J.B. Prognostic factors in metastatic renal carcinoma. J. Urol. 1986;136:376–379.
    1. Tosco L., Van Poppel H., Frea B., Gregoraci G., Joniau S. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur. Urol. 2013;63(4):646–652.
    1. Murthy S.C., Kim K., Rice T.W. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann. Thorac. Surg. 2005;79(3):996–1003.
    1. Ljungberg B., Albiges L., Bensalah K. European urology; 2018. EAU Guidelines on Renal Cell Carcinoma: 2018 Update.
    1. Kothari G., Foroudi F., Gill S., Corcoran N.M., Siva S. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol. 2014:1–10.
    1. Siva S., Kothari G., Muacevic A. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat. Rev. Urol. 2017 Sep;14(9):549.
    1. Siva S., Pham D., Kron T. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective trial. BJU Int. 2017 Nov;120(5):623–630.
    1. Zaorsky N.G., Lehrer E.J., Kothari G. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol. 2019 Sep;2(5):515–523.
    1. Pickering L.M., Mahgoub M.O., Mukherji D. Is observation a valid strategy in metastatic renal cell carcinoma? Curr. Opin. Urol. 2015;25(5):390–394.
    1. Motzer R.J., Escudier B., McDermott D.F. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 2015 Nov 5;373(19):1803–1813.
    1. Motzer R.J., Tannir N.M., McDermott D.F. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 2018 Apr 5;378(14):1277–1290.
    1. Rini B.I., Plimack E.R., Stus V. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 2019 Mar 21;380(12):1116–1127.
    1. McDermott D.F., Lee J.L., Szczylik C. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427. J. Clin. Oncol. May 20, 2018;36(15) 4500-4500, suppl.
    1. Deng L., Liang H., Burnette B. Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 2014 Feb;124(2):687–695.
    1. Filatenkov A., Baker J., Mueller A.M. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin. Canc. Res. 2015 Aug 15;21(16):3727–3739.
    1. Park S.S., Dong H., Liu X. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015 Jun;3(6):610–619.
    1. Cox B.W., Spratt D.E., Lovelock M. International spine radiosurgery consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int. J. Radiat. Oncol. Biol. Phys. 2012;83(5):e597–605.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera